<DOC>
	<DOCNO>NCT00469027</DOCNO>
	<brief_summary>The primary objective establish safety autologous progenitor cell-based gene therapy heNOS patient severe Pulmonary Arterial Hypertension ( PAH ) refractory conventional treatment .</brief_summary>
	<brief_title>Pulmonary Hypertension : Assessment Cell Therapy</brief_title>
	<detailed_description>This two centre , phase I clinical trial . A total 18 patient study use open-label , dose escaling protocol ; three patient enter five dosing panel . An additional three patient enter final dose panel establish safety maximum tolerate dose .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<criteria>Clinical diagnosis idiopathic Pulmonary Arterial Hypertension Familial PAH anorexigen induce PAH Specified 6minute walk distance Intra extra cardiac communication right leave sided circulation Hemodynamic instability Left ventricular ejection fraction &lt; 40 % Thromboembolic event recent hospitalization worsen right side heart failure past 3 month CVP &gt; 20mmHg time research heart catheterization Pregnancy Concurrent hepatitis HIV</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Pulmonary Arterial Hypertension ( PAH )</keyword>
</DOC>